Drug profile · INN
relatlimab
OPDUALAG
relatlimab (OPDUALAG) is a lymphocyte activation gene 3 protein inhibitor.
Drug details — relatlimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.83
Quick answer
relatlimab (OPDUALAG) is a lymphocyte activation gene 3 protein inhibitor.
Key facts
Mechanism of action
Lymphocyte activation gene 3 protein inhibitor
Primary target: Lymphocyte activation gene 3 protein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
FDA Approval VX-009: Market Analysis of Oncodex's Oncolytic Virus Therapy
Explore the implications of FDA-approved VX-009, Oncodex's groundbreaking oncolytic virus therapy, and its potential impact on the cancer treatment market.
Next-Generation Immunotherapy: Beyond PD-1/PD-L1 Inhibition in US Oncology
This article delves into next-generation immunotherapy strategies that extend beyond PD-1/PD-L1 inhibition, highlighting advancements in cancer treatment.
Checkpoint Inhibitor Combinations Melanoma: Phase 3 Data & FDA Insights
This article delves into Phase 3 clinical trial data and FDA insights regarding checkpoint inhibitor combinations, focusing on their efficacy in treating melanoma.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is relatlimab?
relatlimab (OPDUALAG) is a lymphocyte activation gene 3 protein inhibitor.
What is the brand name for relatlimab?
OPDUALAG is a marketed brand name for relatlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.